RCUS peer analysis
Arcus Biosciences (RCUS) against its competitors: price, today's move, 1-year return and market value side by side.
RCUS and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| AGIO Agios Pharmaceuticals | $29.95 | -1.96% | -30.74% | $1.82B |
| BEAM Beam Therapeutics | $25.45 | -1.62% | 1.76% | $2.81B |
| COGT Cogent Biosciences | $29.73 | -4.16% | 82.39% | – |
| DNLI Denali Therapeutics | $18.86 | -0.42% | 15.85% | $3.03B |
| IBRX ImmunityBio | $7.98 | 0.38% | 232.50% | $8.79B |
| LQDA Liquidia | $41.50 | -0.84% | 70.36% | $4.03B |
| OCUL Ocular Therapeutix | $6.71 | -0.30% | -42.45% | $1.53B |
| VRDN Viridian Therapeutics | $25.30 | 2.55% | 7.07% | – |
| RCUS Arcus Biosciences | $17.85 | -1.87% | -9.48% | $2.32B |
- RCUS's peers: AGIO (Agios Pharmaceuticals), BEAM (Beam Therapeutics), COGT (Cogent Biosciences), DNLI (Denali Therapeutics), IBRX (ImmunityBio), LQDA (Liquidia), OCUL (Ocular Therapeutix), VRDN (Viridian Therapeutics).
Updated 2026-11-03 12:34 UTC